Business
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that its Board of Directors (the “Board”) has approved its 2026 Financial Strategy and Capital Management Framework, which includes the authorization of a share repurchase program that the management may undertake in value generation conditions. T
About this update from Psyence Biomedical Ltd.
[{"type":"image","alt":"Psyence Biomedical Ltd.","displaySize":"","headline":null,"caption":"Psyence Biomedical Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/67bd17e4cdd6e19b07d34e625f8a453d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4XQTy8kOrKa7B9604uln6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/67bd17e4cdd6e19b07d34e625f8a453d","width":300,"height":76}},"lazy":false},{"type":"text","content":"NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that its Board of Directors (the “Board”) has approved its 2026 Financial Strategy and Capital Management Framework, which includes the authorization of a share repurchase program that the management may undertake in value generation conditions.","length":498,"tagName":"p"},{"type":"text","content":"The Board’s decision followed a thorough and strategic review of the Company’s financial position, capital structure, prevailing market conditions, and Nasdaq listing considerations. The Strategy is intended to protect shareholder value, and preserve capital to fund planned clinical and regulatory milestones.","length":310,"tagName":"p"},{"type":"text","content":"The Board believes the underlying value of the Company may not be reflected in the current market price of its common shares (“Common Shares”). As a result, depending upon future price movements and other factors, the Board believes that the Common Shares may represent an attractive investment to the Company and that the purchase of the Common Shares would be in the best interests of the Company and its shareholders. Furthermore, the purchases may have the effect of increasing per-share ownership metrics for remaining shareholders by increasing their equity interest in the Company if the repurchased Common Shares are cancelled. Under the approved framework, the Company may repurchase its Common Shares from time to time, subject to liquidity, valuation, regulatory, and market conditions. Any repurchases would be conducted in compliance with applicable securities laws, Nasdaq rules, and applicable corpo...